Efficacy of apraclonidine eye drops in treating ptosis secondary to myasthenia gravis: A pilot clinical trial.
apraclonidine
myasthenia gravis
ocular myasthenia gravis
ptosis
Journal
Muscle & nerve
ISSN: 1097-4598
Titre abrégé: Muscle Nerve
Pays: United States
ID NLM: 7803146
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
revised:
09
05
2023
received:
22
11
2022
accepted:
13
05
2023
medline:
21
7
2023
pubmed:
1
6
2023
entrez:
1
6
2023
Statut:
ppublish
Résumé
Most patients with myasthenia gravis (MG) develop ocular manifestations during their illness and up to 22% may have isolated ocular myasthenia gravis (OMG). Apraclonidine elevates the eyelid by activating alpha-2 receptors on Muller's muscle, an accessory eyelid elevator muscle. In this study we evaluate the effect of apraclonidine in alleviating ptosis secondary to MG. This clinical trial (NCT05045248) was done at the American University of Beirut Medical Center. Patients with ptosis secondary to MG were administered two drops of apraclonidine 0.5% solution to the most affected eye. We measured palpebral fissure height (PF), marginal reflex distance-1 (MRD1), marginal reflex distance-2 (MRD2), and levator function (LF) before drug administration and at 1, 5, 30, and 60 minutes after administration. Ten participants were enrolled in the study. Improvement in all eyelid measurements was noted in all participants as early as 1 minute after apraclonidine administration. From baseline to 60 minutes after administration, average PF increased from 8.8 ± 1.9 mm to 14.2 ± 2.6 mm, MRD-1 from 1.7 ± 1.4 mm to 5.4 ± 2.9 mm, MRD-2 from 7.1 ± 1.3 mm to 8.8 ± 1.7 mm, and LF from 13.4 ± 2.9 mm to 17.5 ± 2.4 mm. All increases were statistically significant. Apraclonidine may alleviate ptosis secondary to MG and may be an effective alternative treatment for this group of patients.
Substances chimiques
apraclonidine
843CEN85DI
Clonidine
MN3L5RMN02
Ophthalmic Solutions
0
Banques de données
ClinicalTrials.gov
['NCT05045248']
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
206-210Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8:475-490.
Sanders DB, Raja SM, Guptill JT, Hobson-Webb LD, Juel VC, Massey JM. The Duke Myasthenia Gravis Clinic Registry: I. Description and demographics. Muscle Nerve. 2021;63:209-216.
Park SJ, Jang SY, Baek JS, Chin S, Jang JW. Distribution of adrenergic receptor subtypes and responses to topical 0.5% apraclonidine in patients with blepharoptosis. Ophthalmic Plast Reconstr Surg. 2018;34:547-551.
Gilhus NE. Myasthenia gravis. N Engl J Med. 2019;375:2570-2581.
Wijemanne S, Vijayakumar D, Jankovic J. Apraclonidine in the treatment of ptosis. J Neurol Sci. 2017;376:129-132.
Cooper-Knock J, Pepper I, Hodgson T, Sharrack B. Early diagnosis of Horner syndrome using topical apraclonidine. J Neuro-ophthalmol. 2011;31:214-216.
Sridharrao B, Badrinath SS. Efficacy and safety of apraclonidine in patients undergoing anterior segment laser surgery. Br J Ophthalmol. 1989;73:884-887.
Chen PL, Hsiao CH, Chen JT, Lu DW, Chen WY. Efficacy of apraclonidine 0.5% in the diagnosis of Horner syndrome in pediatric patients under low or high illumination. Am J Ophthalmol. 2006;142:469-474.
Araujo SV, Bond JB, Wilson RP, Moster MR, Schmidt CM, Spaeth GL. Long term effect of apraclonidine. Br J Ophthalmol. 1995;79:1098-1101.
Klejch W, Vislisel JM, Allen RC. A primer on ptosis. Accessed January 14, 2019. http://www.eyerounds.org/tutorials/ptosis
Yazc B, Beden Ü. Use of 0.5% apraclonidine solution in evaluation of blepharoptosis. Ophthalmic Plast Reconstr Surg. 2008;24:299-301.
Kirkpatrick CA, Shriver EM, Clark TJ, Kardon RH. Upper eyelid response to topical 0.5% apraclonidine. Ophthalmic Plast Reconstr Surg. 2018;34:13-19.
Suzuki S, Murai H, Imai T, et al. Quality of life in purely ocular myasthenia in Japan. BMC Neurol. 2014;14:1-6.